The purpose of the meeting was to reach final agreement on the design of the Phase 3 pivotal clinical trial for PBI-4050 in patients with idiopathic pulmonary fibrosis (IPF).
Based on recommendations from the FDA, enrollment criteria will be greatly simplified such that the study will enroll patients with mild-to-moderate IPF, regardless of whether they are on background standard of care with nintedanib (OFEV) or not. Patients taking pirfenidone will be excluded because of a known drug-drug interaction between pirfenidone and PBI-4050.
The study will provide efficacy data on both PBI-4050 as a stand-alone agent, and as an add-on to nintedanib, and will be part of the dataset to support a simple, all-inclusive indication "for the treatment of IPF."
The primary endpoint is the annual rate of decline in forced vital capacity (FVC).
PBI-4050 has excellent safety and efficacy profiles in a large number of animal models of fibrosis affecting different organs, including the lung, liver, heart, kidney, and pancreas. The effects of PBI-4050 demonstrated in animal models have been replicated in Phase 2 studies in IPF, in Type 2 diabetes with metabolic syndrome, and in Alström syndrome.
Prometic develops bioseparations, plasma-derived therapeutics and small-molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, cancer, and autoimmune diseases/inflammation.The company also offers technologies for large-scale purification of biologics, drug development, proteomics, and the elimination of pathogens to a growing base of industry leaders.
Headquartered in Laval,Canada, the company has R and D facilities in the UK, the US, and Canada; manufacturing facilities in the UK; and commercial activities in the US, Canada, Europe, and Asia.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial